Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease. While Ohtuvayre is projected to become a blockbuster product in COPD alone, its potential extends to other respiratory disorders as well.
Verona Pharma’s COPD drug Ohtuvayre is a single small molecule that blocks two targets to bring patients both bronchodilation and anti-inflammatory effects. Verona executives contend their inhalable drug has key advantages over the last novel COPD medication, the orally administered roflumilast.
There are a number of criteria for selecting the best autism therapy centers. Parents choosing a facility or professionals seeking to improve their offerings should consider certain standards to ensure the right fit.